The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Exploring the use of atezolizumab in combination with R-CHOP in DLBCL
After the successful use of PD-L1 inhibitors in solid tumors, these agents are now being explored in diffuse large B-cell lymphoma (DLBCL). Here, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the preliminary analysis of a Phase I/II study on the use of atezolizumab in combination with R-CHOP in patients with DLBCL (NCT02596971). Presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
